Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name	:BAY 2965501 (BAY2965501)
Cat.No.	:URK-V2451
CAS No.	:2732902-08-6
Molecular Formula	:$C_{20}H_{19}FN_4O_3S$
Molecular Weight	:414.46
Target	:
Solubility	:

Biological Activity

BAY 2965501 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), which is a member of the PRMT family of enzymes responsible for post-translational modification of protein. PRMTs are involved in various cellular processes such as gene expression, DNA damage response, and RNA metabolism. PRMT5 has been shown to be a promising target for cancer therapy due to its role in promoting tumor growth and survival.

BAY 2965501 has demonstrated excellent pharmacological properties in preclinical studies. It exhibits strong anti-proliferative activity against a wide range of cancer cell lines, including those resistant to conventional therapies. BAY 2965501 targets cancer cells by inhibiting their ability to survive and proliferate, while leaving normal cells unaffected.

Recent studies have shown promising results for BAY 2965501 in animal models of cancer. It has shown significant therapeutic efficacy in multiple tumor types, including lung, breast, and colon cancers. BAY 2965501 has also been found to enhance the efficacy of conventional cancer therapies, such as chemotherapy and radiation therapy.

In addition, BAY 2965501 has been found to have a favorable safety profile in preclinical studies. It does not show any significant toxicity or adverse effects on vital organs such as the heart, liver, and kidneys. This is a significant advantage over many existing cancer therapies, which often cause significant toxicity and side effects.

References

1. Nicole Schubert, et al. Cancer Res (2023) 83 (7_Supplement): 2116.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

JACK@UREIKO-CHEM.COM